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Abstract 
 
Objective: The benefit of sentinel lymph node (SLN) biopsy and adjuvant 
therapy for patients with thick (>4mm) melanoma has not been well studied 
in Asian population. We examined the benefit of SLN biopsy and adjuvant 
therapy on prognosis in Japanese thick melanoma patients. 
Materials and methods: A review of the melanoma database collected from 
26 institutions in Japan identified 291 patients with thick melanoma 
between 2005 and 2010. Univariate and multivariate analyses were 
performed to evaluate factors predictive of overall (OS) and disease-free 
survival (DFS). 
Results: Of the 242 thick melanoma patients who received SLN biopsy, the 
results for 96 (40%) were positive. On multivariate analysis, increased 
Breslow thickness (relative risk, 1.11; 95% confidence interval, 1.05-1.17; 
P=0.0002) and SLN metastasis (2.14; 1.04-4.43; P =0.040) were associated 
with poor OS. Increased Breslow thickness (1.11; 1.04-1.18; P =0.0018), 
ulceration (3.11; 1.25-7.72; P=0.014), satellitosis (3.89; 1.62-9.31; P =0.0023) 
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and SLN metastasis (2.24; 1.16-4.36; P =0.017) were associated with DFS. 
Adjuvant chemotherapy had no impact on either OS or DFS. Adjuvant use of 
monthly dermal injection of interferon-b (IFNb) was associated with 
improvement in both OS (0.34; 0.17-0.67; P =0.0022) and DFS (0.42; 
0.20-0.86; P =0.018).  
Conclusions: SLN biopsy provided useful prognostic information and 
adjuvant use of IFNb improved both OS and DFS in Japanese patients with 
thick melanoma. These results were consistent with those of previous studies 
conducted in Caucasians. Therefore, we suggest that SLN biopsy and 
adjuvant IFN should be considered for patients with thick melanoma 
regardless of the Breslow thickness or ethnity. 
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Introduction 
 
 Fifteen to twenty percent of patients with clinically localized melanoma of 
intermediate thickness (1 - 4 mm Breslow thickness) have occult lymph node 
metastasis. Before Morton et al [1] proposed the sentinel lymph node (SLN) 
concept, immediate elective lymphadenectomy was advocated to improve 
tumor staging and possibly survival [2,3] despite the risk or surgery-related 
complications. For patients with intermediate-thickness melanoma, SLN 
biopsy has become the standard method for determining the pathologic 
status of the regional nodal basin[4].  
On the other hand, controversy remains as to whether SLN biopsy has any 
merit for patients with thin melanoma (≦1 mm Breslow thickness) or thick 
melanoma (>4 mm Breslow thickness). Because the risk of nodal metastasis 
for patients with thin melanoma is as low as 5%[4], patients without risk 
factors such as ulceration or mitotic activity are not likely benefit from SLN 
biopsy. Therefore, discussion has centered on identifying a subset of these 
patients who may still benefit from SLN biopsy [5] [6].  
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 The risk of thick melanoma nodal metastasis is reported to be almost 40% 
[7-9]. Moreover, this patient population has a high risk for systemic occult 
disease [10]. Given these facts, the benefit of SLN biopsy in patients with 
thick melanoma is still controversial[8]. On the other hand, some reports 
studying the role of SLN biopsy in thick melanoma showed that the SLN 
status provided important prognostic information[11, 12]. According to those 
studies, patients with no evidence of tumor in the SLN had significantly 
better  disease-free survival (DFS) as well as overall survival (OS) than did 
the SLN-positive patients .  
 Previous large-population studies have all been conducted in Western 
countries. The clinical evidence for Asian patients, especially from 
large-scale studies, is limited; and little is known about melanoma in Asian 
population. This is because melanoma is relatively rare in non-Caucasian 
populations: according to the Surveillance, Epidemiology, and End Results 
(SEER) data from the United States, the incidence of melanoma in Asians is 
about 1 in 100,000 persons as compared to that in Caucasians of 20 in 
100,000 persons (SEER data, 2004-2008; 
http://seer.cancer.gov/statfacts/html/melan.html#incidence-mortality). 
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Moreover, the clinical characteristics such as the pathology, anatomical 
origin, and patient’s prognosis differ significantly among different ethnic 
groups[13]. Therefore, whether previous study results can be applied to 
Asian populations needs to be confirmed. 
 The aim of this study was to evaluate the effect of SLN biopsy and adjuvant 
therapy on Japanese patients with thick melanoma. 
 
 
Materials and methods 
 
The Japanese Melanoma Study is a prospective cohort study involving 26 
centers in Japan that started in 2005. All patients diagnosed as having 
melanoma are registered with this database; so far, 2126 patients have been 
registered. We extracted data from this database that met the following 
requirements: pathologically confirmed primary cutaneous melanoma, 
Breslow thickness >4 mm, clinically lymph node-negative, without elective 
lymph node dissection, without distant metastasis, and records with survival 
time. Because DAVFeron (dacarbazine, nimustine hydrochloride, vincristine, 
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interferon-b, IFN b) therapy is the only adjuvant chemotherapy method 
recommended in the General Rules for Clinical and Pathological Studies on 
Malignant Neoplasms of the Skin[14], we omitted data from patients who 
received other adjuvant chemotherapy so as to standardize the therapeutic 
methods. Finally, 291 consecutive cases were eligible for this analysis. 
SLN biopsy with peritumoral intradermal injection of technetium 99m 
sulfur colloid or phytate colloid and intradermal patent blue dye was 
performed. The SLNs were serial-sectioned with hematoxylin-eosin staining 
and immunohistochemistry for S-100 and HMB-45 as recommended[14] in 
most cases. Survival information was obtained from the registered database.  
 This study was approved by the institutional review board of the University 
of Tsukuba. 
Statistical methods 
The associations between groups were tested using the chi-square test and 
the t test for categorical and continuous characteristics, respectively. Overall 
survival (OS) and disease-free survival (DFS) were calculated for each 
patient beginning from the date of the primary surgery. For OS, patients 
confirmed to be alive were censored using their last contact date. For DFS, 
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patients confirmed to be alive without locoregional relapse or distant 
metastasis were censored using their last contact date. The estimated OS 
and DFS were calculated using the Kaplan-Meier method. The Cox 
proportional hazard models was used to estimate the bivariate association 
between each end point and the available patient/ tumor characteristics and 
the type of adjuvant therapy. The best multivariate model was defined as the 
model that resulted from application of a stepwise regression (forward 
selection) algorithm that automatically eliminated the variables with P 
values over 0.05, until only significant characteristics remained. Significance 
for all statistical tests was defined as a P value over 0.05. All analyses were 
performed with commercially available software (Stat Flex version 6.0; 
Artech, Osaka, Japan). 
 
Results 
 
Patient characteristics 
 The patient characteristics of this study are listed in Table 1. The mean 
age of the patients was 69 years. The median Breslow thickness was 5.9 mm, 
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with a range of 4 to 25 mm. The primary tumor distribution occurred most 
commonly in the foot and was relatively well distributed in the head and 
neck, trunk, and hand. Ulceration was present in 63% of the patients, 
regression in 4%, and satellitosis ini 8%. SLN biopsy was performed in 241 
patients (83%). Adjuvant chemotherapy and IFN-b protocol-2 were 
performed in approximately half of the population (48% and 44%, 
respectively) and IFN-b protocol-1 was performed in just over one quarter of 
the population (28%). 
SLN status  
Of the 291 patients, 50 (17%) did not undergo SLN biopsy. The reason why 
these patients did not do so is unclear, but given the higher average age in 
this group than in the group that did undergo the biopsy (76.8 versus 63.8 
years; t test, P<0.00001), the patients’ elderly age and comorbidities might 
have been determining factors. For patients who did undergo SLN biopsy, 
the median number of harvested SLNs per case was 2 (range, 1-10). In 12 
patients, a SLN biopsy was attempted but failed. 
The SLN was positive in 96 patients (40%). Factors associated with a 
positive SLN are listed in Table 2. Age was not associated with SLN 
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positivity. Female sex was relatively higher in the SLN-positive group than 
in the SLN-negative group (P=0.055). The proportion of the acral lentiginous 
melanoma (ALM) histologic subtype was lower in the SLN-positive group 
than in the SLN-negative group (P=0.011). Breslow thickness is known to be 
strongly predictive of SLN positivity, and the incidence of SLN positivity 
rises significantly with increasing thickness(P=0.03). Other factors such as 
ulceration, regression and satellitosis were not correlated with SLN 
positivity. 
Of the 96 patients found to be SLN-positive, 79 underwent complete lymph 
node dissection (CLND). Of these patients, 23 (29%) had non-SLN 
metastasis. Although we do not have clear reasons for why the SLN-positive 
patients did not received CLND, the higher age of these patients (mean, 73.0 
years) as compared with the patients who did receive CLND (mean, 59.4 
years) might be an essential factor. The SLN status showed no significant 
correlation with treatment choice. 
Survival 
 The mean follow-up for the entire cohort was 24.5 months. During 
follow-up, 83 patients (29%) developed recurrent melanoma and 46 (16%) 
11 
 
died of the disseminated disease. SLN biopsy conferred no survival benefit 
(Figure 1).  
The association between prognostic factors and both OS and DFS were 
studied in patients with thick melanomas who underwent successful SLN 
biopsy. SLN-positive patients had a shorter OS than did SLN-negative 
patients (Figure 2). The 3-year OS for SLN-positive patients was 65% as 
compared with 87% for SLN-negative patients (log-rank method, P<0.005). 
Univariate analysis showed the following 5 factors as significantly predictive 
of OS (Table 3): male sex (relative risk, 2.10; 95% confidence interval [CI], 
1.04- 4.14; increasing Breslow thickness (1.14; 1.08- 1.20; P<0.000001), 
SLN-positivity (2.34; 1.30- 5.34; P=0.0071), satellitosis (3.17; 1.31- 7.63; 
P=0.010), and adjuvant IFN-b (0.31; 0.16- 0.62; P=0.0009). On multivariate 
analysis, the following 3 factors maintained significance (Table 3): Breslow 
thickness (1.11; 1.05- 1.17;  P=0.0002), tumor-positive SLN (2.14; 1.04- 4.43; 
P=0.040) and adjuvant IFN-b (0.34; 0.1- 0.67; P=0.0022).  
Next we examined the effect of these factors on DFS. SLN-positive patients 
had shorter DFS than did SLN-negative patients (Figure 3). The 3-year DFS 
for SLN-positive patients was 52% as compared with 76% for SLN-negative 
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patients (log-rank method, P<0.005). As shown in Table 4, univariate 
analysis showed that DFS was significantly associated with the following 4 
factors: increasing Breslow thickness (relative risk, 1.14; 95% CI, 1.04- 1.21; 
P<0.00001), tumor-positive SLN (2.58; 1.31- 5.10; P=0.0063), presence of 
satellitosis (2.90; 1.32- 6.37; P=0.0080) and adjuvant IFN-b (0.40; 0.20- 0.79; 
P=0.0081). Multivariate analysis showed that presence of ulceration (3.11; 
1.25- 7.72; P=0.014) was also significantly associated with DFS in addition to 
the following 4 factors (Table 4): Breslow thickness (1.09; 1.02- 1.16; 
P=0.014), SLN-positivity (2.59; 1.28- 5.23; P=0.0077), satellitosis (3.89; 1.62- 
9.31; P=0.0023) and adjuvant IFN-b (0.42; 0.20- 0.86; P=0.018) 
 
Discussion 
 
In the current analysis of 291 Japanese patients diagnosed with thick 
melanoma, we discovered that the histologic subtype of ALM was quite 
common, up to 50%. This observation is consistent with previous data 
obtained from other Asian populations[15, 16]. Some reports suggested that 
patients with the histologic subtype of ALM have shorter survival than do 
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patients with other subtypes[15, 17]. Therefore, it was necessary to confirm 
whether the evidence obtained from studies using Caucasian populations 
can be directly applied to patients of Asian populations.  
The median tumor thickness in our study population was 5.9 mm, 
indicating tumor considered as locally advanced and with high risk of 
systemic disease[18]. Although the benefit of SLN biopsy for thick melanoma 
is still controversial[19], recent studies on Caucasian patients with thick 
melanoma showed that the SLN status was an independent prognostic factor 
for both OS and DFS[11, 12]. In the present study, 241 patients underwent 
SLN biopsy, but the remaining 50 patients did not. We could not find any 
survival difference between the patients who underwent SLN biopsy and 
those who underwent nodal observation (Figure 1).  
We found that nearly 42% (96 out of 229) of the patients in this population 
had SLN metastasis, which is a rate similar to those of previous reports [7] 
[21] [11] [12]. As shown in Table 2, SLN-positive patients had a lower rate of 
the ALM subtype and increased Breslow thickness. Other factors including 
ulceration were not statistically correlated with the SLN biopsy results. In 
this analysis, SLN-negative patients had a significantly better OS as well as 
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DFS (log-rank method, P<0.005). The multivariate analysis showed that 
increased Breslow thickness and SLN status affected OS. Previous reports 
concluded that the OS of thick melanoma was affected by the following 
factors: increased Breslow thickness[11, 12], ulceration[7, 12], and SLN 
status[7, 11, 12]. We should note that SLN status was concluded to be an 
independent prognostic factor of OS in all of the studies including ours, that 
focused on thick melanomas[7, 11, 12]. Our results confirmed that the SLN 
status is also an independent prognostic factor for thick melanoma in 
Japanese population. 
In the present study, multivariate analysis showed that increased Breslow 
thickness, ulceration, satellitosis, and SLN status affect DFS. Others have 
also reported the impact of increased Breslow thickness[12, 22], ulceration[7, 
9, 11], and SLN status[7, 9, 11, 12, 22] on DFS. SLN status was identified as 
an independent prognostic factor of DFS, as well as for OS. Our study also 
showed satellitosis to be an independent prognostic factor for DFS; however, 
recent studies[7, 9, 12, 22] failed to show significant association. Gajdos et 
al[11] showed the significance of satellitosis by univariate analysis, but not 
by multivariate analysis. Our results support the inclusion of satellitosis in 
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the current American Joint Committee of Cancer (AJCC) staging system. 
To improve the outcome data and to reduce the risk of recurrence for thick 
melanoma, several efforts have been attempted, including adjuvant 
chemotherapy using dacarbazine (DTIC) or nonspecific immune adjuvants. 
However, such attempts failed to improve survival[23]. To date, the only 
Federal Drug Administration approved adjuvant therapy for thick 
melanoma and/or regional lymph node metastasis is high-dose IFN-a. On the 
other hand, since Yamamoto et al [24] showed that a combination 
chemotherapy regimen using DTIC, nimustine hydrochloride, vincristine, 
and IFN-b (DAVFeron) improved survival in high-risk melanoma, this 
chemotherapy regimen has become widely accepted for the management of 
AJCC stage 2 and stage 3 melanomas in Japan. Adjuvant IFN-b is also 
accepted. However, no randomized controlled study had been conducted to 
prove the impact of DAVFeron and adjuvant IFN-b on DFS or OS. Moreover, 
several cases of DAV therapy-related myelodysplastic syndrome have been 
reported [25]. Although ours is a prospective cohort study, we concluded that 
chemotherapy using the DAV regimen had no effect on DFS and OS. On the 
other hand, IFN-b protocol-2 (3 MU dermal injection of IFN-b once a month 
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continued for at least 1 year) had a significant survival benefit on both DFS 
and OS. This result is consistent with the study by Garbe et al[26] which 
showed that subcutaneous injection of 3 MU IFN-a significantly improved 
both the DFS and the OS of AJCC stage 3 melanoma.  
 In conclusion, SLN biopsy provides important prognostic information in 
thick melanoma, and low-dose IFNb improves both DFS and OS. These 
observations are consistent with the previous studies on Caucasians, with no 
ethnic differences observed. We strongly suggest the routine use of SLN 
biopsy and low-dose IFN therapy in patients with thick melanoma because 
both procedures can be performed safely. Further studies evaluating their 
influence are needed. 
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Figure 1  Kaplan-Meier overall survival analysis for thick primary 
melanoma patients who received sentinel lymph node biopsy or nodal 
observation 
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Figure 2  Kaplan-Meier overall survival analysis for sentinel lymph 
node-positive and –negative patients with thick primary melanoma 
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Figure 3  Kaplan-Meier disease-free survival analysis for sentinel lymph 
node-positive and –negative patients with thick primary melanoma 
 
 
